Tag: the war on (some) drugs

Equity Advocates ‘Correct The Record’ On Biden’s Marijuana Actions And Shortcomings Of Anticipated Schedule III Move

A coalition of drug policy reform advocates is seeking to “correct the record” on the Biden administration’s marijuana policy achievements, calling attention to unfulfilled campaign promises to Black and brown communities on cannabis reform and criticizing the limitations of incremental rescheduling.

During a virtual press briefing organized by the Drug Policy Alliance (DPA) on Wednesday, representatives of multiple equity-focused cannabis organizations pushed back on the administration’s modest reform steps, contending that anything short of ending federal marijuana criminalization would represent a disservice to the communities most impacted under prohibition.

Maritza Perez Medina, director of federal affairs at DPA, stressed during the briefing that moving marijuana to Schedule III under the Controlled Substances Act (CSA), as the U.S. Department of Health and Human Services (HHS) has recommended to the Drug Enforcement Administration (DEA), is “something that our communities cannot accept.”

“As long as marijuana remains anywhere on the CSA, the harms of federal marijuana criminalization will continue,” she said.

Cat Packer, vice chair of the Cannabis Regulators of Color Coalition (CRCC) and director of drug markets and legal regulation at DPA, said the Biden administration’s commentary around its marijuana policy achievements “illustrates the need for Black and brown communities to correct the record of what promises have been made to our communities and whether any promises have been kept.”

President Joe Biden campaigned on a pledge to federally decriminalize marijuana—and he’s said repeatedly that nobody should be incarcerated over cannabis. But despite granting pardons for people who’ve committed certain federal marijuana possession offenses and directing a scheduling review, those broader promises have not yet been achieved.

“Rescheduling marijuana to Schedule III—the outcome that is anticipated to result from the Biden administration’s actions—would continue the very criminalization that Biden said that he would end and is the very type of incrementalism that [Vice President Kamala Harris] criticized in 2020,” Packer said. “Where’s the accountability to Black and brown communities to whom these reforms were promised?”

Keep reading

New York Governor Pushes Big Tech To ‘Step Up’ By Removing Illicit Marijuana Shop Listings

New York’s governor is calling on big tech companies such as Google and Meta to “do the right thing” by taking steps to stop promoting illicit marijuana shops that have proliferated across the state.

During a press briefing on Wednesday, Gov. Kathy Hochul (D) said that social media and search engine companies are passively undermining the legal market that’s being implemented by allowing unlicensed retailers to be featured on their services, giving consumers the false impression that they are legitimate businesses.

‘They’re hurting our legal shops, and we’ve been in touch with these companies, these platforms, and we’ve told them flat out, ‘You need to change this,’” she said.

Hochul added that she doesn’t expect the tech companies to proactively identify and remove illicit shop listings on their own because “they would tell us that they’re not required to.” To that end, she said her message to the businesses is, “let us help you.”

“Let us give you the list of legal vendors. I know who’s legal. We all know who’s legal. And then you have a responsibility to make sure that you’re not posting the locations of illegal shops,” the governor said. “Now I’m calling on all these platforms to step up, do the right thing and be part of the solution. Don’t be complicit in helping jeopardize the public health and the livelihoods of these legitimate business owners.”

At Wednesday’s briefing, Hochul was joined by cannabis stakeholders and advocates, including representatives of organizations that published an open letter to the governor on Tuesday that raised the alarm about social media companies promoting unlicensed retailers.

Keep reading

Ohio Drops Medical Marijuana Patient Fee To 1¢ As New Jersey Offers Free Digital Cannabis Cards

Ohio medical marijuana patients and caregivers will soon only need to pay one penny to obtain or renew their registrations, regulators have announced. And in New Jersey, the state is fully eliminating the cost of obtaining a medical cannabis card.

As Ohio prepares to implement a voter-approved adult-use legalization law, the Division of Cannabis Control (DCC) says that, effective March 4, the annual fees ($50 for patients and $25 for caregivers) will drop to one cent. Once regulators are able to update vendor software, the plan is to completely remove the fee.

“The DCC understands that a one cent charge is not ideal,” it said in a notice on Tuesday, “however, at this time the Division feels it is appropriate and necessary to provide this immediate financial relief for patients and caregivers in the short term while working toward a full fee elimination as soon as the updates to the registry can be made.”

The fee elimination is part of an initial package of rules that DCC released earlier this month to implement adult-use legalization. That rollout currently calls for sales to begin in September, but the governor and lawmakers have pushed for legislation to speed up that process by allowing existing medical cannabis dispensaries to begin selling to adult consumers earlier.

A top Ohio Democratic senator recently said GOP House leadership is doing a “disservice” to the public by failing to advance legislation to expedite marijuana sales.

The Senate did pass a bill in December that would address the issue by allowing existing medical cannabis dispensaries to dually serve patients and adult consumers within 90 days of enactment, in addition to other changes to the initiated statute. But the House hasn’t taken it up, and the chamber has also been considering an alternative package.

Meanwhile, the New Jersey Cannabis Regulatory Commission (NJ-CRC) also announced on Tuesday that, starting on March 1, patients and caregivers will no longer be required to pay a $10 fee to obtain a medical marijuana card.

They will be able to download the cards digitally for free and either save them on their phones or print them out.

“We are excited to offer free digital medicinal cannabis cards to patients in New Jersey,” Jeff Brown, executive director of the NJ-CRC, said in a press release. “Our goal with this initiative is to improve accessibility and convenience for patients who require medical cannabis for their treatment. By offering digital options, we make it more convenient for patients to receive the care they need.”

Brown also recently disclosed that the state has officially surpassed $2 billion in medical and recreational marijuana sales since 2018, and he also encouraged lawmakers to explore the possibility of giving medical cannabis patients a home grow option.

Keep reading

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom.

FDA Deputy Commissioner for Policy, Legislation, and International Affairs Kimberlee Trzeciak discussed the agency’s cannabis and kratom interests during a webinar hosted by the Alliance for a Strong FDA this month.

Asked about issues that are “top of mind” for the agency in 2024 and where officials hope to engage with Congress, Trzeciak said that later this year or next year FDA wants to address setting up “an appropriate regulatory framework for CBD.”

Later in the conversation, the FDA official was asked specifically about how the agency is “prioritizing” its work on cannabis and kratom regulations, and she said officials are taking a number of factors into consideration as they work to address the substances.

“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” she said. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”

“Based on what we know about CBD in particular, we do not think that those products would be able to meet the safety standards that we have in place for foods and dietary supplements today,” she said, referencing the agency’s position after it declined to enact regulations for the non-intoxicating cannabinoid that was legalized under the 2018 Farm Bill.

“What can we do in terms of regulatory tools to ensure that this product is going to be marketed that consumers are clearly aware of what the product is, what is in it and making sure that we have basic information about the marketplace?” Trzeciak said. “I like to think of it as the common regulatory tool that we have across the other products that we regulate.”

She added that FDA wants to “work with Congress on this effort,” including possible rulemaking around CBD product labeling and packaging.

“For example, how can we ensure that the agency knows if there are adverse events that are being reported, so we can identify those trends, making sure that the product is being manufactured or produced in a way that’s safe and quality?” she said.

Kratom reform advocates say the deputy commissioner’s comments represent a “shift” in the agency’s policy perspective on the issue. Historically, FDA hasn’t engaged in the kratom debate as actively as other agencies such as the National Institute on Drug Abuse (NIDA).

Keep reading

South Dakota Senate Passes Strict Ban On Delta-8 THC And Other Intoxicating Hemp Products

The state Senate has voted to pass the original, stricter version of a ban on the widely available, hemp-derived “diet weed” products that induce highs similar to marijuana.

House Bill 1125 had originally targeted a wide swath of products. The gummies, vape pens, pre-rolled joints and smokable flowers can be produced using high concentrations of the psychoactive chemicals present in minuscule amounts in industrial hemp, or using synthetically derived versions of those same chemicals.

The chemical concoctions are an unexpected outgrowth of the legalization of industrial hemp at the federal level. The federal legality of the natural intoxicants made the use of them in large concentrations legal by extension, though there have been questions raised by the Drug Enforcement Administration about the legality of the lab-grown versions.

HB 1125 flip-flopped between which kinds of products would be covered as it moved through the lawmaking process.

Rep. Brian Mulder, R-Sioux Falls, moved his bill through the House Health and Human Services Committee in its original form, but saw it modified on the House floor to target only products made from the lab-grown chemicals, which are sold under names like THC-O.

Rep. Oren Lesmeister, D-Parade, told his fellow representatives that a ban on products made with naturally occurring chemicals would hurt small business owners and hemp growers alike. Under that change, products sold under names like Delta-8 or Delta-10 THC would still be legal to sell.

The House passed Lesmeister’s amendment, then passed HB 1125 on a unanimous vote.

Keep reading

Legalisation is not linked to an increase in cannabis-related psychosis

A study of data from pre and post-cannabis legalisation in Canada has found no increase in admissions to hospitals for cannabis-related episodes of psychosis.

The relationship between cannabis use and episodes of psychosis is a contentious issue that is often raised by opponents of legalisation. Results from previous studies have been mixed, with some finding evidence to suggest cannabis use, particularly in adolescence, can be a cause of psychotic episodes, and others finding no association between the two. 

The present study was published in The Canadian Journal of Psychiatry in February 2024 and used data collected from the three emergency departments (EDs) in Quebec City. The number of admissions for psychosis where evidence of cannabis use was present was compared by researchers to the number of admissions in the 12 months following legalisation. 

Only admissions from adults aged 18 years and above were included in the data, and evidence of cannabis use was obtained from the patient’s medical records and included results of urine tests as well as clinical notes. 

Keep reading

Cannabis May Be ‘Viable Alternative’ Treatment For Dogs With Common Skin Disease, Case Study Shows

Cannabis appears to be a “viable alternative” treatment option for dogs suffering from a common skin disease—especially if they experience adverse side effects from conventional steroid therapies—according to a new case study.

Researchers at the Federal University of Santa Catarina in Brazil published their findings in the journal Frontiers in Veterinary Science this month, detailing the efficacy of full-spectrum CBD oil on a dog with the autoimmune disease discoid lupus erythematosus (DLE).

The condition, which causes hair loss and redness that could progress to lesions, is typically treated with corticosteroids and other medications that can put a strain on a dog’s liver. That’s what was happening with the two-year-old canine at the center of the new case study.

A veterinarian prescribed a full-spectrum oil with a 2:1 THC:CBD ratio, which was administered orally—at first, one drop per day for three days and gradually increasing it “until the optimal dose for symptom control was identified.”

“Within a few weeks, the dog exhibited significant improvement in dermatological signs, accompanied by a concurrent improvement in liver function,” the study says. “Interestingly, the owner reported an improvement in the dog’s behavior shortly after discontinuing prednisolone and within the first day of receiving the cannabis oil.”

“Cannabis derivatives, beyond their pain-relieving prowess, are emerging as potential knights in shining armor against inflammation and immune system overwork in the veterinary world,” the discussion section says. “Unlike traditional drugs, these compounds dance with the body’s own endocannabinoid system (ECS), a master conductor of cellular harmony, homeostasis and diverse functions.”

They added that a key benefit of using cannabis over corticosteroids is that the latter is “limited” to short-term use. In contrast, cannabis products “lack significant side effects and are safe for long-term usage.”

Keep reading

Activists Renew Effort To Use Opioid Settlement Funds To Study Ibogaine For Addiction In Ohio After Kentucky Plan Falls Through

Psychedelic medicine proponents are redirecting their efforts to use millions in opioid-related state settlement money for ibogaine research from Kentucky to Ohio.

The original plan to use $42 million from Kentucky’s opioid settlement fund for psychedelics research fell through late last year after the state’s new attorney general replaced then-Kentucky Opioid Commission Chairman Bryan Hubbard, who was spearheading the ibogaine initiative, with a former Drug Enforcement Administration (DEA) official.

Now Hubbard has joined ResultsOHIO, a division of the Ohio Treasurer’s Office, where he will be partnering with the Reaching Everyone in Distress (REID) Foundation in hopes of securing a portion of that state’s opioid settlement funds to promote psychedelics clinical trials for substance misuse treatment.

“I’m honored to work with the REID Foundation and the people of Ohio to bring hope and healing to veterans and families being torn apart by the opioid crisis,” Hubbard said in a press release. “The development of ibogaine as a treatment option for opioid-dependent individuals is a moral imperative.”

A Kentucky commission focused on opioid overdose abatement held several meetings last year to go over the ibogaine initiative that’s since fizzled out in that state under the new attorney general. Members heard testimony from military veterans, parents, psychologists and other advocates—including former Texas Gov. Rick Perry (R)—about the therapeutic potential of the psychedelic.

Like Kentucky, Ohio has been hard hit by the opioid overdose crisis. And under the settlement agreement, the state is expected to receive about $1 billion that could be used for various programs and services to help mitigate the public health issue.

The plan for the ibogaine effort is to seek funding for the research through a public-private partnership, while also exploring the creation of a specific program under ResultsOHIO to facilitate the partial settlement distribution, Psychedelic Alpha reported.

Keep reading

Connecticut Lawmakers File Psilocybin Decriminalization Bill Despite Governor’s Concerns

Connecticut lawmakers have revived an effort to decriminalize low-level possession of psilocybin, despite the governor’s office recently indicating that it has concerns about the psychedelics reform.

A new bill filed by the legislature’s Joint Judiciary Committee and cosponsored by Rep. David Michel (D) would make possession of up to one-half an ounce of psilocybin punishable by a $150 fine, without the threat of jail time.

A second or subsequent violation would carry a fine of at least $200 but not more than $500. A person who pleads guilty or no contest on two separate occasions would be referred to a substance misuse treatment program

Police would be require to seize and destroy any amount of the psychedelic they find under the measure, HB 5297. Possession of more than a half-ounce of psilocybin would be considered a Class A misdemeanor.

An earlier version of the psilocybin decriminalization bill passed the House last year but did not advance in the Senate.

Lawmakers and activists held an informational forum last month to discuss the therapeutic potential of substances such as psilocybin and potential pathways to allow for regulated access.

“We are inspired by the leadership of the Judiciary Committee to continue the conversation on how to responsibly decriminalize psilocybin and stand ready to assist the legislature and the governor in working through any concerns,” Jason Ortiz, policy director of Connecticut for Accessible Psychedelic Medicine who also serves as director of strategic initiatives for the Last Prisoner Project, told Marijuana Moment.

“While the bill is a great start, there’s still room for improvement by including home cultivation and retroactive relief for those who were criminalized for simply seeking a better quality of life,” he said.

Meanwhile, as the legislation is being introduced, the office of Gov. Ned Lamont (D) has signaled that it may face a major barrier to enactment.

“The governor has concerns about broad decriminalization of mushrooms,” spokesperson David Bednarz said last month, noting that at the time it was “a bit too early to speculate” because a 2024 bill had not yet been filed yet.

Keep reading

Hunter Biden Claims Not Doing Crack Is a ‘Fight for the Future of Democracy’

Hunter Biden not doing crack is a “fight for the future of democracy,” the president’s son told Axios Monday in reference to former President Donald Trump’s bid for reelection.

Hunter’s attempt to somehow tie the fate of the nation to his legal imperative to abstain from drug use fits his long-running narrative of victimhood.

Hunter pleaded not guilty to gun charges in October and underwent random drug testing. Judge Christopher Burke released him on several conditions, including that he not use alcohol or ingest controlled substances.

“I have something much bigger than even myself at stake,” Hunter said about his legal battles. “We are in the middle of a fight for the future of democracy.”

“Most importantly, you have to believe that you’re worth the work, or you’ll never be able to get sober. But I often do think of the profound consequences of failure here,” Hunter said.

“I don’t care whether you’re ten years sober, two years sober, two months sober or two hundred years sober — your brain at some level is always telling you there’s still one answer,” he said about his history of addictions and parmesan cheese.

Hunter is set to testify before the House impeachment inquiry on Wednesday. It is unknown if he will actually appear for the interview. Hunter failed to show last time he said he would appear.

Keep reading